All Type of News
Competition will get severe between Viread and Baraclude
Expected to be applied for the insurance benefit on the solo therapy for multiple drug resistant patients, the Gilead’s hepatitis type B treatment, Viread (tenofovir), has kept its increasing curve.
It is expected th...
Dong-A looks forward to achieving the top pharmaceutical company with its 4 new drugsThe Dong-A ST’s constant R&D investment and effort launched the 24th domestic new drug.
Dong-A ST (CEO and President Chan-il Park) announced on the 17th that its first FDA-appr...
|
The 3-way competition among DHL, FedEx and World Courier for the special medicine shipping
International express parcel companies, DHL and FedEx, have participated in the ‘Bio Korea’ conference, held from the 8th and 10th of April.
The two companies have focused on promoting the special medicine shipping a...
“The corporate pharmacy won’t be promoted” mentioned in the internal reference of the ruling party
The government triggered severe opposition of the pharmaceutical society to the announcement of the corporate pharmacy at the Trade and Investment Organization on December 2013. Is it why? The governmental discussion ...
Why would many MRs with high sales retire recently?
“The medical representatives (MR), also known as specialists who have recently retired from their companies, are personnel with high sales. There are now more retirements than turnovers among MRs.”
The trend of job t...
Launches of complexes and generics is about to change the statin market
‘Lipitor (atorvastatin)’ and ‘Crestor (generic name: rosuvastatin)’, which have divided the hyperlipidemia treatment market into tow, encountered the situation to defend attacks of complexes and generics this year and...
2 of 5 pharmaceutical distribution companies find warning signs in soundness of financial structures
It is known that 2 of 5 pharmaceutical distribution companies exceeded over 400% in the debt ratio, having warning signs in soundness of their financial structures.
According to the YakupDotCom’s analysis result of 2...
Pradaxa and Eliquis will get insurance benefits for deep vein thrombosis
Insurance benefits of ‘Pradaxa’ and ‘Eliquis’ will be available on treating and preventing reoccurrence of deep vein thrombosis (DVT) and pulmonary Embolism (PE).
The Ministry of Health and Welfare made an official a...
Pfizer and GSK had two different performances last yearThe two companies once competing for the first and second in sales in the pharmaceutical industry, Pfizer Korea and GSK Korea, have received contrary management performance in 2...
|
“The new drug development is the only way to overcome the situation,” reflecting decreases in salesman and increases in researchers
For the past 8 years, pharmaceutical companies have reorganized personnel structures.
While the number of salesman has constantly decreased from 35.3% in 2005 to 29.2% in 2013 with 6.1% differences, the number of res...
